Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement on voluntary disclosure of the production line of new oral solid dosage form workshop and hard capsule dosage form passing the pharmaceutical GMP compliance inspection.
Nanjing Securities Co., Ltd.'s verification opinion on the expected daily related party transactions of Jiangsu Novartis Ausino Bio-pharmaceutical Co., Ltd. in 2024.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement regarding the expected new related trade for the year 2024.
Verification opinions on the change of part of the raised funds investment projects of Jiangsu Notai Ausen Pharmaceutical Co., Ltd, submitted by Nanjing Securities Co., Ltd.
Opinion on verification of Jiangsu Notai Ausanuo Biopharmaceutical Co., Ltd.'s use of part of the raised funds to increase capital to fully-owned subsidiaries for the implementation of the raised investment project by Nanjing Securities Co., Ltd.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement of Resolutions of the 17th Meeting of the Third Supervisory Board.
Jiangsu Sinopep-Allsino Biopharmaceutical: Public opinion management system.
Jiangsu Sinopep-Allsino Biopharmaceutical: Information Disclosure Management System
Jiangsu Sinopep-Allsino Biopharmaceutical: Investor Relations Management System
Jiangsu Sinopep-Allsino Biopharmaceutical: Registration and management system for insiders with information.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement of the Resolution of the Twentieth Meeting of the Third Board of Directors.
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement on the voluntary disclosure of the pharmaceutical registration certificate for oseltamivir phosphate granules.
Inspection opinions of Zhongtianyun Certified Public Accountants (Special General Partnership) on the response to the inquiry letter on the 2023 annual report of Jiangsu Nuotai Aosainuo Biopharmaceutical Co., Ltd.
Nordtech Biotech Investor Relations Activity Record Form (2024-002)
Jiangsu Sinopep-Allsino Biopharmaceutical: Announcement on holding the results briefing for the first quarter of 2023 and 2024
Nanjing Securities Co., Ltd.'s inspection opinion on the initial public offering of some restricted shares of Jiangsu Nuotai Aosainuo Biopharmaceutical Co., Ltd. on the listing and circulation of some restricted shares
Nanjing Securities Co., Ltd.'s 2023 continuous supervision report on Jiangsu Nuotai Aosainuo Biopharmaceutical Co., Ltd.
Nootech Investor Relations Activity Record Form (2024-001)
Nootai Biotech: Independent Director's Debriefing Report (Qu Feng)
Nootech Biotech: Independent Director's Debriefing Report (Hu Wenyan)
No Data